Philip M. Reaper

7.0k citations

19 papers · 5.4k indexed · 2 hit papers · h-index 16

Co-authors: Stephen P. Jackson Fabrizio d’Adda di Fagagna Gabriele Saretzki Nigel P. Carter Thomas von Zglinicki Heike Fiegler Philippa Carr John R. Pollard
Topics: DNA Repair Mechanisms (15 papers)Cell death mechanisms and regulation (8 papers)Cancer-related Molecular Pathways (7 papers)
Cited by: Aging Oncology Physiology
Journals: Nature Nature Communications Cancer Research
Partner nations: United Kingdom United States Germany

In The Last Decade

Philip M. Reaper

19 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

A DNA damage checkpoint response in telomere-initiated senescence

2003 2.1k citations Fabrizio d’Adda di Fagagna, Philip M. Reaper et al. Nature profile →
Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATM

2004 983 citations Ian Hickson, Yan Zhao et al. Cancer Research profile →

Peers

Countries citing papers authored by Philip M. Reaper

Since Specialization

Citations

This map shows the geographic impact of Philip M. Reaper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philip M. Reaper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philip M. Reaper more than expected).

Fields of papers citing papers by Philip M. Reaper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philip M. Reaper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philip M. Reaper. The network helps show where Philip M. Reaper may publish in the future.

Co-authorship network of co-authors of Philip M. Reaper

This figure shows the co-authorship network connecting the top 25 collaborators of Philip M. Reaper. A scholar is included among the top collaborators of Philip M. Reaper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philip M. Reaper. Philip M. Reaper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy 2019 ·Frank T. Zenke,Astrid Zimmermann,Heike Dahmen,Brian Elenbaas,John D. Pollard,Philip M. Reaper,(unknown),(unknown),(unknown),Andree Blaukat	1
2	Abstract 369: Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy 2019 ·Cancer Research ·Frank T. Zenke,Astrid Zimmermann,Heike Dahmen,Brian Elenbaas,John R. Pollard,Philip M. Reaper,Shubha Bagrodia,Mary E. Spilker,Christiane Amendt,Andree Blaukat	15
3	Rational Design of 5-(4-(Isopropylsulfonyl)phenyl)-3-(3-(4-((methylamino)methyl)phenyl)isoxazol-5-yl)pyrazin-2-amine (VX-970, M6620): Optimization of Intra- and Intermolecular Polar Interactions of a New Ataxia Telangiectasia Mutated and Rad3-Related (ATR) Kinase Inhibitor 2019 ·Journal of Medicinal Chemistry ·Ronald M. A. Knegtel,Jean‐Damien Charrier,Steven J. Durrant,(unknown),Mike O’Donnell,(unknown),Somhairle MacCormick,David P. Kay,Joanne L. Pinder,(unknown),Heather Twin,Matthew R. Griffiths,Philip M. Reaper,(unknown),Steve Young,Julian M.C. Golec,John R. Pollard	41
4	ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A 2016 ·Nature Communications ·Chris T. Williamson,Rowan Miller,Helen N. Pemberton,Samuel E. Jones,James Campbell,Asha Konde,Nicholas Badham,Rumana Rafiq,Rachel Brough,Aditi Gulati,Colm J. Ryan,Jeffrey C. Francis,(unknown),Andrew R. Reynolds,Philip M. Reaper,John R. Pollard,Alan Ashworth,Christopher J. Lord	270
5	Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities 2015 ·Cell Reports ·Kumar Sanjiv,Anna Hagenkort,José Manuel Calderón‐Montaño,Tobias Koolmeister,Philip M. Reaper,Oliver Mortusewicz,Sylvain A. Jacques,Raoul Kuiper,Niklas Schultz,Martin Scobie,Peter Charlton,John R. Pollard,Ulrika Warpman Berglund,Mikael Altun,Thomas Helleday	112
6	Development of pharmacodynamic biomarkers for ATR inhibitors 2014 ·Molecular Oncology ·Tao Chen,Fiona K. Middleton,(unknown),Philip M. Reaper,John R. Pollard,Nicola J. Curtin	15
7	Structure of human Bloom's syndrome helicase in complex with ADP and duplex DNA 2014 ·Acta Crystallographica Section D Biological Crystallography ·M.K. Swan,(unknown),Adam Tanner,Philip M. Reaper,(unknown),(unknown),John R. Pollard,Peter Charlton,Julian M.C. Golec,J. A. Bertrand	58
8	ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses 2014 ·Cancer Research ·Rozenn Jossé,Scott E. Martin,Rajarshi Guha,Pinar Ormanoglu,Thomas D. Pfister,Philip M. Reaper,Christopher S. Barnes,Julie Jones,Peter Charlton,John R. Pollard,Joel Morris,James H. Doroshow,Yves Pommier	121
9	Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970 2014 ·Oncotarget ·Amy B. Hall,(unknown),Yuxin Wang,Diane M. Boucher,Brenda K. Eustace,Yong Gu,Brian Hare,Mac Johnson,Howard Li,(unknown),Cheryl Murphy,Darin Takemoto,(unknown),Mark Wood,Peter Charlton,Jean‐Damien Charrier,Brinley F. Furey,Julian M.C. Golec,Philip M. Reaper,John R. Pollard	149
10	The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy 2012 ·Cancer Biology & Therapy ·Remko Prevo,Emmanouil Fokas,Philip M. Reaper,Peter Charlton,John R. Pollard,W. Gillies McKenna,Ruth J. Muschel,Thomas Brunner	191
11	Targeting radiation-resistant hypoxic tumour cells through ATR inhibition 2012 ·British Journal of Cancer ·Isabel M. Pires,Monica M. Olcina,Selvakumar Anbalagan,John R. Pollard,Philip M. Reaper,Peter Charlton,W. Gillies McKenna,Ester M. Hammond	127
12	Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation 2012 ·Cell Death and Disease ·Emmanouil Fokas,Remko Prevo,John R. Pollard,Philip M. Reaper,Peter Charlton,Bart Cornelissen,Katherine A. Vallis,Ester M. Hammond,Monica M. Olcina,W. Gillies McKenna,Ruth J. Muschel,Thomas Brunner	278
13	Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR 2011 ·Nature Chemical Biology ·Philip M. Reaper,Matthew R. Griffiths,Joanna Long,Jean‐Damien Charrier,Somhairle MacCormick,Peter Charlton,Julian M.C. Golec,John R. Pollard	476
14	Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents 2011 ·Journal of Medicinal Chemistry ·Jean‐Damien Charrier,Steven J. Durrant,Julian M.C. Golec,David P. Kay,Ronald M. A. Knegtel,Somhairle MacCormick,Michael Mortimore,Mike O’Donnell,Joanne L. Pinder,Philip M. Reaper,(unknown),(unknown),Stephen Young,John R. Pollard	192
15	Rapid PIKK-Dependent Release of Chk1 from Chromatin Promotes the DNA-Damage Checkpoint Response 2005 ·Current Biology ·Veronique A. J. Smits,Philip M. Reaper,Stephen P. Jackson	151
16	The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes 2004 ·Oncogene ·(unknown),Philip M. Reaper,Andrew R. Pettitt,Paul D. Sherrington	40
17	Activation of the DNA Damage Response by Telomere Attrition: A Passage to Cellular Senescence 2004 ·Cell Cycle ·Philip M. Reaper,Fabrizio d’Adda di Fagagna,Stephen P. Jackson	45
18	Identification and Characterization of a Novel and Specific Inhibitor of the Ataxia-Telangiectasia Mutated Kinase ATMbreakdown → 2004 ·Cancer Research ·Ian Hickson,Yan Zhao,Caroline J. Richardson,(unknown),Niall M.B. Martin,(unknown),Philip M. Reaper,Stephen P. Jackson,Nicola J. Curtin,Graeme C.M. Smith	983
19	A DNA damage checkpoint response in telomere-initiated senescencebreakdown → 2003 ·Nature ·Fabrizio d’Adda di Fagagna,Philip M. Reaper,(unknown),Heike Fiegler,Philippa Carr,Thomas von Zglinicki,Gabriele Saretzki,Nigel P. Carter,Stephen P. Jackson	2124

About Philip M. Reaper

Philip M. Reaper is a scholar working on Aging, Oncology and Toxicology, having authored 19 papers that have together received 5.4k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (15 papers), Cell death mechanisms and regulation (8 papers) and Cancer-related Molecular Pathways (7 papers). The work is most often cited by research in Aging (323 citations), Oncology (2.0k citations) and Physiology (1.7k citations). Philip M. Reaper has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Stephen P. Jackson, Fabrizio d’Adda di Fagagna, Gabriele Saretzki, Nigel P. Carter, Thomas von Zglinicki, Heike Fiegler, Philippa Carr, John R. Pollard, Peter Charlton and Nicola J. Curtin. Their work appears in journals such as Nature, Nature Communications and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact